OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS

KADIM BAYAN¹, MUSTAFA KEMAL ÇELEN², TUBA DAL³, CELAL AYAZ², RECEP TEKIN², İREM AKDEMIR⁴, TUĞBA SARI⁵, ÖZGÜR GÜNAL⁶, SAVAŞ CUMALI EFE⁷

¹Diyarbakır Sultan Hospital, Department of Gastroenterology, Diyarbakır, Turkey - ²Dicle University School of Medicine, Department of Infectious Disease and Clinical Microbiology, Diyarbakır, Turkey - ³Ankara Yildirim Beyazit University, School of Medicine, Department of Medical Microbiology, Ankara, Turkey - ⁴Batman Region State Hospital, Department of Infectious Disease and Clinical Microbiology, Batman, Turkey - ⁵Turkish National Public Health Agency, Ankara, Turkey - ⁶Samsun Training & Educational Hospital, Department of Infectious Diseases and Clinical Microbiology, Samsun, Turkey - ⁷Batman Region State Hospital, Department of Gastroenterology, Batman, Turkey

Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investi- gate the efficacy and safety of DAA (OBV/PTV/r + DSV ± RBV) treatment regimen in patients with HCV.

Materials and method: A total of 57 adults with HCV infection who initiated treatment DAA were included in this study. Baseline,4 weeks and 12 weeks data including clinical characteristics, laboratory results and adverse events (AEs) were recorded.

Results: One patient left treatment at the second week. The majority of patients were female 33 (57.9 %) and HCV GT1b (80.7%). Of the patients, 43 (75.4 %) patients were treatment experienced with pegylated interferon ± RBV and 14 (25.6%) patients were naive. Ten (17.5%) patients had liver cirrhosis, 3 patients renal insufficiency, 7 patients diabetes mellitus, and 6 patients hyper- tension. Mean baseline ALT and HCV RNA levels was 48.58±25.8 U/L and 2857661±7231938 IU/ml, respectively. At the end of the week 4, one patient had >15 IU/mL HCVRNA level, HCVRNA was negative in remaining patients and mean ALT levels was 34.7±17.01 U/L. Three (5.3%) patient had AEs. At the end of the week 12, HCVRNA was negative in all patients, mean ALT levels was 29.3±12.2 U/L, 8 (14%) patients had AEs.

Conclusion: DAA was a safe and effective therapy with 100% SVR rate and low treatment discontinuation rate (1.7 %) in patients with HCV GT1, GT1a and GT1b. This was well tolerated and efficient treatment aproach in patients with liver cirrhosis, renal insufficiency, diabetes mellitus, and hypertension.